Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings results on February 20, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $0.10, missing the consensus estimate of $0.14 by $0.04 per share. Revenue came in at $185.2M, beating the estimate of $183.0M.
Amicus Therapeutics's stock moved following the earnings release. The stock currently trades at $14.35 with a market capitalization of $3.1B.